Study design of the phase III ADELA trial of elacestrant with or without everolimus in <i>ESR1</i> -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor

José Manuel Pérez-García, Antonio Llombart-Cussac, Elena López-Miranda, Alfonso Cortes, Isabel Garcia-Fructuoso, Elena Galve-Calvo, Manuel Ruiz-Borrego, Alba Cochs, Antonia Perelló-Martorell, Serafin Morales, Laia Boronat Ruiz, Sara Marín-Liébana, Cristina Saavedra, Isabel Blancas, Carmen Hinojo, Mariana López Flores, Sylvain Ladoire, Peter Schmid, Gilles Freyer, Rui Rui Zhang, Daniel Alcalá-López, Juliana Carvalho-Santos, Olga Boix, Carlos H. Barrios, Giuseppe Curigliano, Rupert Bartsch, Anne Clair Hardy Bessard, Tomer Wasserman, Javier Cortés

Open source

DOI: 10.1080/14796694.2026.2753794
Published: 2026-10-31
Container: Future Oncology
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2753794,
  title = {Study design of the phase III ADELA trial of elacestrant with or without everolimus in
                    <i>ESR1</i>
                    -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor},
  author = {José Manuel Pérez-García and Antonio Llombart-Cussac and Elena López-Miranda and Alfonso Cortes and Isabel Garcia-Fructuoso and Elena Galve-Calvo and Manuel Ruiz-Borrego and Alba Cochs and Antonia Perelló-Martorell and Serafin Morales and Laia Boronat Ruiz and Sara Marín-Liébana and Cristina Saavedra and Isabel Blancas and Carmen Hinojo and Mariana López Flores and Sylvain Ladoire and Peter Schmid and Gilles Freyer and Rui Rui Zhang and Daniel Alcalá-López and Juliana Carvalho-Santos and Olga Boix and Carlos H. Barrios and Giuseppe Curigliano and Rupert Bartsch and Anne Clair Hardy Bessard and Tomer Wasserman and Javier Cortés},
  year = {2026},
  journal = {Future Oncology},
  doi = {10.1080/14796694.2026.2753794},
  url = {https://doi.org/10.1080/14796694.2026.2753794}
}

RIS

TY  - JOUR
TI  - Study design of the phase III ADELA trial of elacestrant with or without everolimus in
                    <i>ESR1</i>
                    -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor
AU  - José Manuel Pérez-García
AU  - Antonio Llombart-Cussac
AU  - Elena López-Miranda
AU  - Alfonso Cortes
AU  - Isabel Garcia-Fructuoso
AU  - Elena Galve-Calvo
AU  - Manuel Ruiz-Borrego
AU  - Alba Cochs
AU  - Antonia Perelló-Martorell
AU  - Serafin Morales
AU  - Laia Boronat Ruiz
AU  - Sara Marín-Liébana
AU  - Cristina Saavedra
AU  - Isabel Blancas
AU  - Carmen Hinojo
AU  - Mariana López Flores
AU  - Sylvain Ladoire
AU  - Peter Schmid
AU  - Gilles Freyer
AU  - Rui Rui Zhang
AU  - Daniel Alcalá-López
AU  - Juliana Carvalho-Santos
AU  - Olga Boix
AU  - Carlos H. Barrios
AU  - Giuseppe Curigliano
AU  - Rupert Bartsch
AU  - Anne Clair Hardy Bessard
AU  - Tomer Wasserman
AU  - Javier Cortés
PY  - 2026
JO  - Future Oncology
DO  - 10.1080/14796694.2026.2753794
UR  - https://doi.org/10.1080/14796694.2026.2753794
ER  -

APA

Pérez-García, J. M., Llombart-Cussac, A., López-Miranda, E., Cortes, A., Garcia-Fructuoso, I., Galve-Calvo, E., Ruiz-Borrego, M., Cochs, A., Perelló-Martorell, A., Morales, S., Ruiz, L. B., Marín-Liébana, S., Saavedra, C., Blancas, I., Hinojo, C., Flores, M. L., Ladoire, S., Schmid, P., Freyer, G., Zhang, R. R., Alcalá-López, D., Carvalho-Santos, J., Boix, O., Barrios, C. H., Curigliano, G., Bartsch, R., Bessard, A. C. H., Wasserman, T., & Cortés, J. (2026). Study design of the phase III ADELA trial of elacestrant with or without everolimus in <i>ESR1</i> -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor. Future Oncology. https://doi.org/10.1080/14796694.2026.2753794

Source records

crossref · retrieved 2026-11-09T14:08:27.851Z